Compile Data Set for Download or QSAR
maximum 50k data
Found 462 with Last Name = 'boyle' and Initial = 'rg'
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402004(5-[[5-[4-[(1-isopropyl-4-piperidyl)amino]-2-methox...)
Affinity DataIC50:  0.00400nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402004(5-[[5-[4-[(1-isopropyl-4-piperidyl)amino]-2-methox...)
Affinity DataIC50:  0.00400nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402003(5-[[5-[4-[(1-ethyl-4-piperidyl)amino]-2-methoxy-ph...)
Affinity DataIC50:  0.00500nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402003(5-[[5-[4-[(1-ethyl-4-piperidyl)amino]-2-methoxy-ph...)
Affinity DataIC50:  0.00500nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402002(5-[[5-[2-methoxy-4-[(1-methyl-4-piperidyl)amino]ph...)
Affinity DataIC50:  0.00700nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402002(5-[[5-[2-methoxy-4-[(1-methyl-4-piperidyl)amino]ph...)
Affinity DataIC50:  0.00700nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402035(5-[[5-[4-[(1-ethyl-4-piperidyl)methyl-methyl-amino...)
Affinity DataIC50:  0.00800nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402035(5-[[5-[4-[(1-ethyl-4-piperidyl)methyl-methyl-amino...)
Affinity DataIC50:  0.00800nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402036(5-[[5-[4-[(isobutylamino)methyl]-2-methoxy-phenyl]...)
Affinity DataIC50:  0.0120nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402036(5-[[5-[4-[(isobutylamino)methyl]-2-methoxy-phenyl]...)
Affinity DataIC50:  0.0120nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM401974(5-[[5-[2-methoxy-4-[(3R)-3-methylpiperazin-1-yl]ph...)
Affinity DataIC50:  0.0160nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM401985(5-[[5-[4-[(3R)-4-ethyl-3-methyl-piperazin-1-yl]-2-...)
Affinity DataIC50:  0.0160nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM401985(5-[[5-[4-[(3R)-4-ethyl-3-methyl-piperazin-1-yl]-2-...)
Affinity DataIC50:  0.0160nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM401984(5-[[5-[4-[(3R)-3,4-dimethylpiperazin-1-yl]-2-metho...)
Affinity DataIC50:  0.0160nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM401984(5-[[5-[4-[(3R)-3,4-dimethylpiperazin-1-yl]-2-metho...)
Affinity DataIC50:  0.0160nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM401974(5-[[5-[2-methoxy-4-[(3R)-3-methylpiperazin-1-yl]ph...)
Affinity DataIC50:  0.0160nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402031(5-[[5-[4-[[(3R)-1-isopropylpyrrolidin-3-yl]oxymeth...)
Affinity DataIC50:  0.0190nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402031(5-[[5-[4-[[(3R)-1-isopropylpyrrolidin-3-yl]oxymeth...)
Affinity DataIC50:  0.0190nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402030(5-[[5-[4-[[(3R)-1-ethylpyrrolidin-3-yl]oxymethyl]-...)
Affinity DataIC50:  0.0210nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402033(5-[[5-[4-[(1-ethyl-4-piperidyl)methyl]-2-methoxy-p...)
Affinity DataIC50:  0.0210nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402030(5-[[5-[4-[[(3R)-1-ethylpyrrolidin-3-yl]oxymethyl]-...)
Affinity DataIC50:  0.0210nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402033(5-[[5-[4-[(1-ethyl-4-piperidyl)methyl]-2-methoxy-p...)
Affinity DataIC50:  0.0210nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402010(5-[[5-[2-methoxy-4-[(2R)-4-ethylmorpholin-2-yl]phe...)
Affinity DataIC50:  0.0220nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM401957(5-[[5-[2-methoxy-4-(1-methylazetidin-3-yl)phenyl]-...)
Affinity DataIC50:  0.0220nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM401957(5-[[5-[2-methoxy-4-(1-methylazetidin-3-yl)phenyl]-...)
Affinity DataIC50:  0.0220nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402010(5-[[5-[2-methoxy-4-[(2R)-4-ethylmorpholin-2-yl]phe...)
Affinity DataIC50:  0.0220nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402018(5-[[5-[4-[[(2S)-1-ethylpyrrolidin-2-yl]methoxy]-2-...)
Affinity DataIC50:  0.0230nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402018(5-[[5-[4-[[(2S)-1-ethylpyrrolidin-2-yl]methoxy]-2-...)
Affinity DataIC50:  0.0230nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402020(5-[[5-[4-[(cyclopropylmethylamino)methyl]-2-methox...)
Affinity DataIC50:  0.0250nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402020(5-[[5-[4-[(cyclopropylmethylamino)methyl]-2-methox...)
Affinity DataIC50:  0.0250nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM401914(5-[[5-[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]...)
Affinity DataIC50:  0.0260nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402034(5-[[5-[4-[(1-isopropyl-4-piperidyl)methyl]-2-metho...)
Affinity DataIC50:  0.0260nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM401906(5-[[5-[2-methoxy-4-[(tetrahydropyran-4-ylamino)met...)
Affinity DataIC50:  0.0260nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402034(5-[[5-[4-[(1-isopropyl-4-piperidyl)methyl]-2-metho...)
Affinity DataIC50:  0.0260nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM401906(5-[[5-[2-methoxy-4-[(tetrahydropyran-4-ylamino)met...)
Affinity DataIC50:  0.0260nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM401914(5-[[5-[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]...)
Affinity DataIC50:  0.0260nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402029(5-[[5-[4-[[(3S)-1-isopropylpyrrolidin-3-yl]oxymeth...)
Affinity DataIC50:  0.0270nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402009(5-[[5-[2-methoxy-4-[(2R)-4-methylmorpholin-2-yl]ph...)
Affinity DataIC50:  0.0270nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402009(5-[[5-[2-methoxy-4-[(2R)-4-methylmorpholin-2-yl]ph...)
Affinity DataIC50:  0.0270nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402029(5-[[5-[4-[[(3S)-1-isopropylpyrrolidin-3-yl]oxymeth...)
Affinity DataIC50:  0.0270nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM120931(US8716287, 64)
Affinity DataIC50:  0.0300nMpH: 7.5Assay Description:The compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set out below. Reaction Buffer: Base R...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402038(5-[[5-[4-[(1-isopropyl-4-piperidyl)methyl-methyl-a...)
Affinity DataIC50:  0.0310nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402038(5-[[5-[4-[(1-isopropyl-4-piperidyl)methyl-methyl-a...)
Affinity DataIC50:  0.0310nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM401904(5-[5-(4-{[(1-cyclopropane-carbonyl-piperidin-4-ylm...)
Affinity DataIC50:  0.0340nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM401904(5-[5-(4-{[(1-cyclopropane-carbonyl-piperidin-4-ylm...)
Affinity DataIC50:  0.0340nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402028(5-[[5-[4-[[(3S)-1-ethylpyrrolidin-3-yl]oxymethyl]-...)
Affinity DataIC50:  0.0410nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402028(5-[[5-[4-[[(3S)-1-ethylpyrrolidin-3-yl]oxymethyl]-...)
Affinity DataIC50:  0.0410nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402000(5-[[5-[4-[(1-ethyl-4-piperidyl)methylamino]-2-meth...)
Affinity DataIC50:  0.0430nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402000(5-[[5-[4-[(1-ethyl-4-piperidyl)methylamino]-2-meth...)
Affinity DataIC50:  0.0430nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required co...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Cascadian Therapeutics

US Patent
LigandPNGBDBM402017(5-[[5-[4-[[(2R)-1-isopropylpyrrolidin-2-yl]methoxy...)
Affinity DataIC50:  0.0440nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 462 total ) | Next | Last >>
Jump to: